RxDoctor Payments Data

Thomas Ruff, DO

Interventional Cardiology · Dayton, OHNPI 1639178304

Payments from drug & device makers

$602in general payments, 2019–2025

Across 25 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$178
  • Novartis$131
  • Biotronik Inc.$115
  • Abbott$46
  • Medtronic$27
  • Amgen$25
  • plus $80 from 5 others

What the payments were for

  • Food & beverage$57696%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$602 in reported general payments places this provider in the 10th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$217,453
Medicare patients
641
Services billed
3,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban493$482,560
Repatha SureclickEvolocumab141$193,024
XareltoRivaroxaban197$192,448
EntrestoSacubitril/Valsartan127$143,723
JardianceEmpagliflozin24$26,833
Praluent PenAlirocumab14$17,780
FarxigaDapagliflozin Propanediol24$16,440
Carvedilol947$6,480
Carvedilol ErCarvedilol Phosphate12$6,157
ClopidogrelClopidogrel Bisulfate710$5,566
Prasugrel Hcl44$5,484
Atorvastatin Calcium711$5,198
Metoprolol Succinate462$5,115
Nifedipine ErNifedipine147$4,844
Amiodarone Hcl323$4,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$192,448197 claims
NovartisEntresto$131$143,723127 claims
AstraZenecaFarxiga$14$16,44024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →